BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) founder Lars Lannfelt will be presented with the Lifetime Achievement Award in Alzheimer's Disease Therapeutic Research at the Clinical Trials for ...

Donanemab and another new drug for Alzheimer’s called Lecanemab have been billed as a huge step forward in research ...

CAMBRIDGE, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: BIIB) announced upcoming data presentations and programming at ...

Donanemab, the most effective treatment yet for the disease, has been banned on the health service despite regulators ...

Key Presentations and Symposia: Transitioning from Clinical Trial to Clinical Practice for Long-Term Lecanemab Treatment in Early Alzheimer's Disease: Perspectives from an Alzheimer's Disease ...

The UK’s National Institute of Health and Care Excellence (NICE) said the drug provided only a small benefit to patients.

Diagnosed with mild cognitive impairment (MCI) in 2018, Mr Almond, from Esher, took part in two 18-month trials for donanemab ...

Health spending watchdog said costs could not justify benefits after treatment slowed cognitive decline by around four to ...

The Dementia Trials Accelerator (DTA) – which will be spearheaded by the UK Dementia Research Institute (UK DRI) and Health ...

Bybit, the world's second-largest cryptocurrency exchange by trading volume, announces the WSOT Copy Trading Fest, inviting ...